Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.
about
Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individualsVirological features associated with the development of broadly neutralizing antibodies to HIV-1Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep SequencingDiverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 bindingIDEPI: rapid prediction of HIV-1 antibody epitopes and other phenotypic features from sequence data using a flexible machine learning platformCross-Neutralizing Antibodies in HIV-1 Individuals Infected by Subtypes B, F1, C or the B/Bbr Variant in Relation to the Genetics and Biochemical Characteristics of the env GeneComputational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residuesAntigenicity-defined conformations of an extremely neutralization-resistant HIV-1 envelope spike.Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies.Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infectionsPlasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.Human immunodeficiency virus type-1 (HIV-1) continues to evolve in presence of broadly neutralizing antibodies more than ten years after infection.Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models.Rapid conformational epitope mapping of anti-gp120 antibodies with a designed mutant panel displayed on yeastEnvelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.A mechanistic understanding of allosteric immune escape pathways in the HIV-1 envelope glycoprotein.Genetic and neutralization sensitivity of diverse HIV-1 env clones from chronically infected patients in ChinaHIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans.Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trialAntibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved.Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational methodepitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals.How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?CATNAP: a tool to compile, analyze and tally neutralizing antibody panelsPGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.Association of enhanced HIV-1 neutralization by a single Y681H substitution in gp41 with increased gp120-CD4 interaction and macrophage infectivity.Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive ImmunizationCross-reactive broadly neutralizing antibodies: timing is everything.Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization BreadthSomatic Populations of PGT135-137 HIV-1-Neutralizing Antibodies Identified by 454 Pyrosequencing and BioinformaticsAntigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains.HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity.Genetic signatures of HIV-1 envelope-mediated bystander apoptosis.Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site.Neutralizing antibodies and control of HIV: moves and countermoves.Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo.Histidine 375 Modulates CD4 Binding in HIV-1 CRF01_AE Envelope Glycoproteins.
P2860
Q24635002-56890DC3-542F-4221-BD11-959641CBDCF4Q27025177-492F036A-77AA-43CD-AE9D-3205884C8BB5Q27671696-EABEBA69-7DA1-415A-A69D-1367B7B10D94Q27675486-5C45E524-5504-450A-9992-3729C17D57E1Q28543211-8DC034C4-9F33-4361-BD98-FB448F3D7344Q28554907-CBA91EFC-B515-44C2-89DB-5877C388BC30Q30644992-92199A73-16B8-4921-9A14-67988F05E015Q33620194-862E4456-9AA3-438F-B368-AC6D4FE706E4Q34016211-DC4435B7-5AF1-4F64-A815-7AD9AFDCEB6EQ34042642-5ABF439B-A2EE-463A-93F2-842D69B429B4Q34374835-B86BFFE6-D32F-4C7B-B56D-384CAC21C8C7Q34407843-6523A142-F3A9-41F1-9943-BBA3B64A0979Q34455457-BA8DFEAF-C333-4513-ADD0-B1FCDA15DA18Q34480254-A1DFF10C-BEC7-4F89-992E-92482074148EQ34594513-AC187C5E-FCF4-4310-A730-041410D8E9C9Q34733504-42EBCFB7-B694-4FC1-A625-F51658D8BFC4Q34800408-98D6FEFC-EE60-48E5-B524-0856D337B989Q34990575-9DEF26FF-C866-4C6A-A906-88205AAFE2E2Q35043417-B31B9472-80BF-460D-B0EC-D5B6EA0648EAQ35073270-59A45C95-D1E7-4F30-AD38-6693E8380FE4Q35124761-05FCE9AE-BC21-4797-81E4-A0B6A921780EQ35192660-5DB0CFCB-93FA-4E53-8C69-44B6187C1D25Q35653703-74435177-8011-4A1B-B74A-BDE7C96737EEQ35810109-A783F76A-1597-4257-A8E6-B0E600BBC4FDQ35868102-1F3290AE-D9D1-4B44-801E-A4260747DF5AQ35883032-856ED7BE-555B-48C6-AC11-F5E212715A68Q35956940-DE227C2A-B839-4CFF-AC7E-1601B1BF7F04Q36081789-E4C4C28E-135F-46F5-8522-140DA9DB9529Q36105782-7C56DE4E-67F8-472E-94D3-19347439D7B5Q36194234-DD6F91A1-4719-4A20-86C5-88BC1A6B59D2Q36231944-940003B4-20DE-4C28-A13E-D27FAF56A920Q36760169-89077471-A5BF-48D3-85E0-E1DDF1730443Q37069837-4DD3214D-2845-48EA-AE60-7CD65394C57FQ37123109-26498897-AB58-4709-A057-149C43BCE079Q37360774-A268BD99-D1AF-49ED-B2F9-746F7DAA6A9EQ37536431-178D2DC2-64A2-42A7-97C3-F7D53F16C4DCQ37729781-6CC651CF-24B1-4074-9B0F-04E74C78AF5AQ37971867-E993A245-6654-4586-937C-A7020A94A85DQ38652858-8F0D6E7B-B821-40A7-A752-C1DE3D10E6D0Q38727214-CAE80024-D1F5-443C-B07C-BF9576BC697A
P2860
Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Genetic signatures in the enve ...... oadly neutralizing antibodies.
@ast
Genetic signatures in the enve ...... oadly neutralizing antibodies.
@en
type
label
Genetic signatures in the enve ...... oadly neutralizing antibodies.
@ast
Genetic signatures in the enve ...... oadly neutralizing antibodies.
@en
prefLabel
Genetic signatures in the enve ...... oadly neutralizing antibodies.
@ast
Genetic signatures in the enve ...... oadly neutralizing antibodies.
@en
P2093
P2860
P50
P1476
Genetic signatures in the enve ...... oadly neutralizing antibodies.
@en
P2093
Alan S Lapedes
Amit Kumar
Anurag Sethi
Haili Tang
Hongmei Gao
Kelli Greene
Marcus G Daniels
Michael S Seaman
P2860
P304
P356
10.1371/JOURNAL.PCBI.1000955
P50
P577
2010-10-07T00:00:00Z